Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
UTICORT is a topical corticosteroid cream containing betamethasone benzoate, approved in 1974 for inflammatory and pruritic dermatological conditions. It works by reducing inflammation, itching, and associated skin manifestations through topical corticosteroid mechanism of action. The product is administered as a cream applied directly to affected skin areas.
As a legacy topical corticosteroid approaching loss of exclusivity with 30% competitive pressure, the brand team is likely focused on defending market share against generics rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on UTICORT offers limited career growth due to its LOE-approaching lifecycle and zero linked job openings; this role is best suited for professionals seeking stability in a mature product or gaining experience in generic transition management. Career progression on this product is constrained by declining market dynamics and organizational de-prioritization.
Worked on UTICORT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo